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OBJECTIVE — The Indian Diabetes Prevention Programme-1 (IDPP-1) showed that lifestyle
modiﬁcation (LSM) and metformin were effective for primary prevention of diabetes in subjects
with impaired glucose tolerance (IGT). Among subjects followed up for 3 years (n  502), risk
reductions versus those for the control group were 28.5, 26.4, and 28.2% in LSM, metformin
(MET),andLSMplusMETgroups,respectively.Inthisanalysis,therolesofchangesinsecretion
and action of insulin in improving the outcome were studied.
RESEARCH DESIGN AND METHODS — For this analysis, 437 subjects (93 subjects
with normoglycemia [NGT], 150 subjects with IGT, and 194 subjects with diabetes) were
included. Measurements of anthropometry, plasma glucose, and plasma insulin at baseline and
at follow-up were available for all of them. Indexes of insulin resistance (homeostasis model
assessmentofinsulinresistance)and-cellfunction(insulinogenicindex[I/G]:30-minfasting
insulin divided by 30-min glucose) were also analyzed in relation to the outcome.
RESULTS — Subjects with IGT showed a deterioration in -cell function with time. Individ-
uals with higher insulin resistance and/or low -cell function at baseline had poor outcome on
follow-up.Inrelationtonoabnormalities,thehighestincidenceofdiabetesoccurredwhenboth
abnormalities coexisted (54.9 vs. 33.7%, 
2  7.53, P  0.006). Individuals having abnormal
insulinresistance(41.1%)orabnormalI/G(51.2%,
24.87,P0.027vs.noabnormalities)
hadlowerincidence.Normal-cellfunctionwithimprovedinsulinsensitivityfacilitatedreversal
to NGT, whereas deterioration in both resulted in diabetes. The beneﬁcial changes were better
with intervention than in the control group. Intervention groups had higher rates of NGT and
lower rates of diabetes.
CONCLUSIONS — In the IDPP-1 subjects, beneﬁcial outcomes occurred because of im-
proved insulin action and sensitivity caused by the intervention strategies.
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P
rimary prevention studies in diabe-
teshavebeendoneinsubjectswitha
high risk for diabetes, such as those
with impaired glucose tolerance (IGT)
(1–6) or with a history of gestational dia-
betes mellitus (7). Lifestyle modiﬁcation
(LSM) (1–5) and/or pharmacological
agents such as metformin (MET) (1,5)
and glitazones (6) have been shown to be
effective in reducing the rate of conver-
sion of IGT to diabetes in different ethnic
groups. The beneﬁts are seen in associa-
tion with weight reduction in the obese
population (1,2) or without signiﬁcant
weight changes in relatively nonobese
population (3,5). The mechanisms that
result in the beneﬁcial changes are asso-
ciated with two important pathophysio-
logical components, namely impaired
secretion and impaired action of insulin.
The Indian Diabetes Prevention Pro-
gramme-1 (IDPP-1) had shown that mod-
erate, but consistent, LSM or use of MET
reducedtheriskofdeteriorationofIGTto
diabetes by 28% in relation to that in a
controlgroupwhohadnointerventionin
a3-yearfollow-upperiod(5).Combining
LSM with MET showed no added beneﬁt.
IGT, an intermediate state in the
natural history of type 2 diabetes, is
characterized by a worsening in insulin
resistance and insulin secretion (8). Asian
Indians have higher rates of insulin resis-
tance than Europeans and other white
populations despite being relatively
nonobese (9,10).
The chief pathophysiological compo-
nents of type 2 diabetes, namely impaired
secretion and action of insulin are detect-
able many years before the diagnosis of
clinical diabetes (11). A combined occur-
rence of both defects due to gradual dete-
rioration, eventually results in diabetes.
This analysis was done to identify the
changes in insulin secretion and insulin
action that produced the improved out-
come with the primary prevention strate-
gies in the IDPP-1 cohort.
RESEARCH DESIGN AND
METHODS— In the IDPP-1, 531
subjects (421 male and 110 female) aged
35–55yearswererecruited(5).Screening
was performed using 2-h postglucose
capillary glucose measurement, and con-
ﬁrmatory diagnosis was made by a stan-
dard oral glucose tolerance test (OGTT)
with a 75-g glucose load. Subjects found
to have IGT on two occasions (2-h post-
glucose levels of 7.8–11.1 mmol/l) ac-
cordingtothecriteriaoftheWorldHealth
Organization (12) were included in the
program. All eligible subjects were ran-
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group 1 (control), standard health care
advice; group 2, advice on LSM; group 3,
treatment with 500 g/day MET; and
group 4, LSM plus MET. The primary
outcome measure was new-onset type 2
diabetes. The measurements were done
during semiannual reviews. If a diagnosis
ofdiabeteswasmade,itwasconﬁrmedby
an OGTT as per the World Health Orga-
nization criteria (12). Over a median fol-
low-upperiodof30months,502subjects
were available for follow-up, and the cu-
mulative incidences of diabetes were 55,
39.3, 40.5, and 39.5%, respectively, in
the four groups; the risk reduction rela-
tive to the control group was 28.5% with
LSM, 26.4% with MET, and 28.2% with
LSM plus MET. Numbers (percentage) of
subjects with normoglycemia (NGT) in
the four groups were 32 (24.1%), 35
(35.8%),39(30.5%),and38(31.4%),re-
spectively. The study protocol was ap-
proved by the ethics committee of the
institution. Informed consent was ob-
tained for all subjects.
Plasma glucose was measured using
the glucose-oxidase peroxidase method
on a Hitachi autoanalyzer 912 with the
reagents supplied by Roche Diagnostics
(Mannheim, Germany). A1C was esti-
mated by the immunoturbidimetric
method (Roche Reagents). The cutoff
value for normal was 6.0%.
Plasma insulin was measured using a
radioimmunoassay kit (DiaSorin, Salug-
gia, Italy). The assay had a sensitivity of
24 pmol/l, and the intra- and interassay
coefﬁcient of variations were 10%. In-
sulin resistance was calculated using ho-
meostasis model assessment (HOMA-IR)
(13). The insulinogenic index (I/G) was
calculated using the difference in the val-
ues of 30-min and fasting plasma insulin
(picomoles per liter) divided by the 30-
min glucose value (millimoles per liter)
(14). Cutoff values for normal HOMA-IR
were 4.1 (15) and 28 for I/G (16).
The relative risk reduction in the in-
cidenceofdiabetescomparedwiththatin
the control group was similar in the three
intervention groups. Hence, the present
analysis was done in the control group
versus all intervention groups combined.
All of the relevant data for this analy-
sis were available for 437 subjects of the
502 subjects followed up for a median of
30 months. Comparative analyses of
baseline and 3rd-year data were done for
subjects with NGT and IGT. For the dia-
betic group, the baseline data were com-
pared with the corresponding values
recorded at the time of diagnosis of dia-
betes.ThenumbersofsubjectswithNGT,
IGT, and diabetes were 93, 150, and 194,
respectively.
Variables included in the analysis
were BMI, waist circumference, plasma
glucose, plasma insulin values (0, 30, and
120 min during an OGTT), HOMA-IR
values,andI/G.Thesebaselinevariables
in the subgroup of 437 analyzed were
similar to those of the original cohort of
531 subjects. The differences at the 3rd
year from the baseline value were calcu-
lated. Data were computed for control
and intervention groups.
Changes in plasma glucose, insulin,
HOMA-IR, and I/G were analyzed an-
nually in the total group (control and in-
tervention) in relation to their glucose
tolerance status. In addition, annual
HOMA-IR and I/G were compared with
the respective baseline values for each in-
tervention group.
Statistical analysis
Means  SD of the variables were cal-
culated for normally distributed vari-
ables. Inter- and intragroup variations
were tested using paired or unpaired t
tests as relevant. Data for plasma insulin,
Table1—Comparisonofdataatbaselineandat3rd-yearreviewincontrolversusintervention
groups
Control Intervention
P
Intergroup
Intragroup
control
Intragroup
intervention
n 116 321
BMI (kg/m
2)
Basal 26.0  3.0 25.5  3.4 0.185
Follow-up 26.4  3.1 25.7  3.3 0.036 0.0001
Waist circumference (cm)
Basal 89.3  7.4 89.1  8.8 0.815
Follow-up 90.8  7.6 90.0  8.7 0.426 0.007 0.002
Glucose (mmol/l)
Fasting
Basal 5.5  0.8 5.4  0.7 0.305
Follow-up 6.5  1.8 6.1  1.5 0.025 0.0001 0.0001
30-min
Basal 9.3  1.7 9.5  1.9 0.174
Follow-up 11.0  2.9 10.6  2.5 0.114 0.0001 0.0001
120-min
Basal 8.6  0.7 8.5  0.7 0.198
Follow-up 10.9  4.0 9.9  3.2 0.009 0.0001 0.0001
A1C (%)
Basal 6.2  0.5 6.2  0.5 0.481
Follow-up 6.4  1.2 6.1  0.9 0.016 0.140 0.215
Insulin (pmol/l)
Fasting
Basal 120 114 0.164
Follow-up 108 102 0.361 0.091 0.029
30-min
Basal 432 450 0.920
Follow-up 363 387 0.599 0.004 0.0001
120-min
Basal 636 558 0.021
Follow-up 510 510 0.776 0.0001 0.003
HOMA-IR
Basal 4.8 4.5 0.115
Follow-up 4.6 4.5 0.130 0.194 0.293
I/G
Basal 36.3 33.7 0.632
Follow-up 24.0 27.2 0.220 0.0001 0.0001
DataaremeansSD(valueswerecomparedusingpairedorunpairedttests)ormedians(comparisonswere
done using median tests).
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bution and hence median values are
shown. Inter- and intragroup compari-
sons were done using a Mann-Whitney U
test and Wilcoxon’s signed-rank test, re-
spectively. A 
2 test was done to compare
intergroup results. Cox regression analy-
ses were done to identify the variables
predictive of conversion to diabetes or to
NGT. For diabetes, baseline and the cor-
responding values recorded at the time of
diagnosiswereusedforanalysis.ForNGT
and IGT, baseline and 3rd-year values
were analyzed. Cox regression analyses
showed that the outcome measures were
inﬂuencedinthecontrolandintervention
groups by similar baseline and follow-up
variables.However,inthecontrolgroupa
few variables showed weaker association,
which failed to reach statistical signiﬁ-
cance (P  0.078 for HOMA-IR). This
was probably due to the smaller sample
size in this group. Hence, considering the
uniformity of results, the ﬁnal regression
analysis was done in the total sample,
combining control and intervention
groups. The control group was included
asanindependentvariable.Thestatistical
packageSPSSforWindows(version10.0;
SPSS, Chicago, IL) was used. P  0.05
was considered to be signiﬁcant.
RESULTS— For this analysis, 437
subjects were included. At the end of the
study at the 3rd year, subjects with NGT,
IGT, and diabetes were 93, 150, and 194,
respectively. Table 1 shows the compara-
tive data at baseline and at the 3rd-year
reviewinthecontrol(n116)versusthe
intervention groups (n  321). The base-
line values of anthropometry and bio-
chemical variables were similar in both
groups except for a higher plasma insulin
value at 120 min in the control group
(P  0.021). At the review, BMI was
higher in the control versus the interven-
tion group (P  0.036). Plasma glucose
increased signiﬁcantly in both groups in
the 3rd year. As expected, the increase
wasmoresigniﬁcantinthecontrolgroup.
At the 3rd year, the total A1C value in-
creased in the control group (not signiﬁ-
cant), whereas it showed a signiﬁcant
(P  0.016) reduction in the intervention
group. Signiﬁcant decreases in plasma in-
sulin values were seen in both groups. Al-
though the median HOMA-IR values
showed no signiﬁcant changes, the I/G
decreased signiﬁcantly in both groups.
Outcomes of glucose tolerance at the
3rd year were analyzed in relation to the
biochemicalabnormalitiescategorizedon
the basis of the baseline values of
HOMA-IR (abnormal 4.1) and I/G
(abnormal 28) (Table 2). The preva-
lence of diabetes was the highest in group
4 with both abnormalities (54.9%, 
2 
7.53, P  0.006 vs. normal group [group
1]) followed by group 3 with a -cell
defect(51.2%,
2  4.87,P  0.027vs.
group1).PrevalenceofNGTwashigher
inthenormalgroup,buttheintergroupdif-
ferences were not statistically signiﬁcant.
Table 3 shows the baseline and fol-
low-up values of HOMA-IR and I/G in
the control and in the total intervention
group in relation to glucose tolerance sta-
tus at the follow-up. The pattern of
changes in insulin resistance and I/G
were similar in individual intervention
groups, but minor statistical variations
were seen due to smaller sample sizes
(data not shown). Development of diabe-
tes occurred mostly in individuals who
had higher values of insulin resistance
and lower values of I/G at the baseline.
On follow-up, both functions deterio-
ratedfurther.Ontheotherhand,subjects
who reverted to NGT showed improve-
ment in insulin sensitivity, and secretion
of insulin remained in normal ranges.
Cox regression analyses adjusted for
baseline age, BMI, and waist circumfer-
ence showed that lower 120-min plasma
glucose ( 0.029, hazard ratio [HR]
0.972,P0.011),lowerHOMA-IR(
0.167, HR 0.846, P  0.008), and
higher I/G (0.016, HR 1.016, P 
0.002) at baseline and reduction in
HOMA-IR ( 0.152, HR 0.859, P 
0.005) and improved I/G (0.015,
HR 1.015, P  0.001) improved glucose
tolerance from IGT to NGT. For diabetes,
the risk was higher in those with lower
120-mininsulinvalues(0.006,HR
0.994, P  0.007), higher HOMA-IR
(0.172, HR 1.187, P  0.0001), and
lower I/G ( 0.015, HR 0.985, P 
Table 2—Outcome of glucose tolerance at 3rd year in relation to the status of baseline
HOMA-IR and I/G
Group 1 Group 2 Group 3 Group 4
Status of IR, I/G Both normal IR abnormal I/G abnormal Both abnormal
n 92 168 86 91
HOMA-IR 3.1 6.1 2.6 5.7
I/G 45.8 51.2 15.2 17.3
Outcome at 3rd year
NGT 25 (27.2) 34 (20.2) 17 (19.8) 17 (18.6)
IGT 36 (39.1) 65 (38.7) 25 (29.1) 24 (26.3)
Diabetes 31 (33.7) 69 (41.1) 44 (51.2)* 50 (54.9)†‡
Dataaremediansorn(%).*
24.87,P0.027vs.group1;†
27.53,P0.006vs.group1;‡
24.03,
P  0.045 vs. group 2. IR, insulin resistance.
Table 3—Status of insulin resistance and insulinogenic index in relation to the glucose toler-
ance status in the control and intervention groups
Control (n  116) Intervention (n  321)
HOMA-IR I/G HOMA-IR I/G
NGT (n  93)
n 15 15 78 78
Basal 4.4 32.6 4.5 40.9
Follow-up 3.2 (0.078) 41.1 3.5 (0.021) 35.6
IGT (n  150)
n 39 39 111 111
Basal 4.5 39.6 4.4 38.7
Follow-up 4.1 39.5 4.0 31.9 (0.002)
Diabetes (n  94)
n 62 62 132 132
Basal 5.4 34.7*† 4.6 27.2
Follow-up 6.9 (0.007)*† 15.7 (0.0001)*† 5.4 (0.0001)*† 17.9 (0.0001)*†
Data are medians. Signiﬁcant P values shown are for intragroup comparisons of follow-up vs. baseline
(Wilcoxon rank test). Intergroup diabetes comparisons were done with a Mann-Whitney U test. *P 0.001
vs. NGT; †P 0.001 vs. IGT.
Insulin secretion and sensitivity in the IDPP-1
1798 DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 care.diabetesjournals.org0.003) at baseline and an increase in
HOMA-IR (0.118, HR 1.126, P 
0.0001), and a reduction in I/G (
0.016, HR 0.984, P  0.001) increased
the hazard for diabetes.
Figure 1 shows the changes in
HOMA-IRandI/Ginrelationtothecor-
responding baseline values in subjects
who had NGT, IGT, and diabetes, at each
annual follow-up. In the NGT group, in-
sulin resistance decreased signiﬁcantly
at all follow-up visits, I/G showed
improvement in year 1 and remained
normal at other periods. Those who con-
tinued to have IGT showed no signiﬁcant
changes in insulin resistance. Value of
I/G showed a signiﬁcant reduction in
the 3rd year. Subjects with diabetes
showed increased insulin resistance and
decreased I/G at all time periods.
CONCLUSIONS — Signiﬁcant re-
ductions in incident diabetes with inter-
ventions in the IDPP-1 were due to
improvementin-cellfunctionandinin-
sulin sensitivity. Diabetes developed
when insulin resistance and -cell func-
Figure1—MedianvaluesofHOMA-IR(A,leftpanel)andI/G(A,rightpanel)werecalculatedinrelationtoglycemicstatus(NGT,IGT[B],and
diabetes[C])atannualfollow-up.Themedianvaluesatthe1st-,2nd-,and3rd-yearfollow-upincomparisonwiththecorrespondingbaselinevalues
in these participants are shown in each category of glucose tolerance. A: 1st year n  160, 2nd year n  155, 3rd year n  93. B: 1st year n  201,
2ndyearn152,3rdyearn150.C:1styearn70,2ndyearn60,3rdyearn64.u,baseline;o,follow-up.*P0.05vs.baselinevalues.
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curred when insulin sensitivity improved
and -cell function remained normal. In
the intervention group (total or each), a
higher proportion of subjects reverted to
NGT and a smaller proportion developed
diabetes compared with the control
group.
Although the biochemical mecha-
nisms causing diabetes and reversal to
NGT were similar in the control and in-
tervention groups, the beneﬁts seen with
inventions were due to augmented bene-
ﬁcialchangesininsulinsensitivityandin-
sulin secretion. Subjects with impaired
fasting glucose or IGT have impaired
phase I insulin secretion, which may ex-
plain their high risk for conversion to di-
abetes (17).
In subjects with IGT, a time-related
deterioration in the I/G was noted. Nor-
mal -cell function with an improved
sensitivity of insulin had favored reversal
to NGT, whereas a deterioration in both
functions resulted in diabetes. Individu-
als with higher insulin resistance and/or
lower -cell capacity at the baseline had a
predisposition to the adverse outcome.
These ﬁndings seen in the univariate and
multivariate analyses agree with the se-
quence of changes described by Festa et
al. (18) in the development of diabetes
from NGT to diabetes in a longitudinal
study. The Diabetes Prevention Pro-
gramme(DPP)alsodemonstratedthatthe
better preventive effect of intensive life-
style was due to improved insulin sensi-
tivity concomitant with preservation of
-cell function (19). Treatment with
metformin also demonstrated similar
changes, although to a lesser degree than
withintensivelifestylechanges.TheFinn-
ish Diabetes Prevention Study (DPS) had
shownsimilareffectsoflifestylemodiﬁca-
tion (20). In our study, a moderate, but
sustained, lifestyle modiﬁcation and/or
metformin produced similar beneﬁcial
changes.Theseeffectswerenotassociated
with weight loss, unlike in the DPP and
DPS studies (19,20). Probably a redistri-
bution of body fat, which is shown to oc-
cur with enhanced physical activity (21),
couldhaveimprovedinsulinsensitivityin
our study subjects. At follow-up, BMI in-
creased only in the control group,
whereas waist circumference increased in
both groups. The increase was signiﬁ-
cantly less in the intervention groups.
Compromised -cell function is de-
tectable in pre-diabetic individuals long
before the onset of type 2 diabetes
(11,18). The importance of declining
-cellfunctioninthetransitionofNGTto
IGTandIGTtodiabeteshasbeendemon-
strated in a longitudinal study in Pima In-
dians (22). The Insulin Resistance
Atherosclerosis Study addressed the lon-
gitudinal changes in -cell function in a
period of 5.2 years in subjects with NGT,
IGT, and diabetes in a multiethnic popu-
lation (18). The results showed that the
mean insulin sensitivity, measured as an
index (SI) from a frequently sampled in-
travenous glucose tolerance test, declined
in all glucose tolerance categories with
time. Importantly, it was demonstrated
that on follow-up, the glucose tolerance
status was principally maintained by the
change in acute insulin response. A com-
pensatory increase in insulin secretion
maintained NGT; IGT status was due to a
failure to increase insulin secretion and
decreasedinsulinsecretionledtodiabetes
(18). The results of the DPP (19) and the
Troglitazone in Prevention of Diabetes
(TRIPOD) study (7) had also demon-
strated the pivotal role of -cell dysfunc-
tion in the conversion of IGT to diabetes.
-Cell function is enhanced by improved
insulinsensitivity,andthepreservationof
-cell function decreases the conversion
of IGT to diabetes.
Subjectswithlowerbaseline120-min
plasma glucose were found to have a
higher probability of reversal to NGT,
which could be explained by the absence
of the above pathophysiological compo-
nents. A negative association between
baseline 120-min plasma insulin re-
sponse and development of diabetes in
this study was in agreement with similar
ﬁndings by Saad et al. (23).
The HOMA-IR index derived from
the product of fasting glucose and insulin
concentrations primarily reﬂects hepatic
insulin resistance. It has been demon-
strated that there is a 70% concordance
between muscle insulin resistance and
liver insulin resistance in the same sub-
jects (24).
A limitation of this study is that the
estimates of insulin secretion and action
have been made by calculations based on
the OGTT and not by a “gold standard”
test (euglycemic clamp study). The in-
dexes are being used in epidemiological
studies because the clamp studies are not
feasibleinlargenumbers.Theearly-phase
insulin secretion calculated as the I/G
correlates with the ﬁrst-phase insulin re-
lease measured during hyperglycemic in-
sulin clamp (25).
In summary, the IDPP-1 study
showed that a decrease in insulin secre-
tion combined with reduced insulin sen-
sitivity resulted in diabetes and an
improvement in these functions facili-
tated reversal to NGT in subjects with
IGT. The rate of conversion to diabetes
was signiﬁcantly lower and reversal to
NGT was higher in subjects who received
interventions than in the control group.
Thisresultindicatedthatbeneﬁcialeffects
of interventions work through mecha-
nisms of preserving -cell function and
improving insulin sensitivity even in sub-
jects not having a reduction in body
weight.
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